165 related articles for article (PubMed ID: 31251903)
21. Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer.
Yang Z; Shah K; Busby T; Giles K; Khodadadi-Jamayran A; Li W; Jiang H
J Clin Invest; 2018 Aug; 128(8):3605-3618. PubMed ID: 29870403
[TBL] [Abstract][Full Text] [Related]
22. A chromatin modulator sustains self-renewal and enables differentiation of postnatal neural stem and progenitor cells.
Shah K; King GD; Jiang H
J Mol Cell Biol; 2020 Jan; 12(1):4-16. PubMed ID: 31065682
[TBL] [Abstract][Full Text] [Related]
23. DPY30 functions in glucose homeostasis via integrating activated histone epigenetic modifications.
Liu B
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):286-290. PubMed ID: 30448059
[TBL] [Abstract][Full Text] [Related]
24. Structural basis of nucleosome recognition and modification by MLL methyltransferases.
Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J
Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071
[TBL] [Abstract][Full Text] [Related]
25. A phosphorylation switch on RbBP5 regulates histone H3 Lys4 methylation.
Zhang P; Chaturvedi CP; Tremblay V; Cramet M; Brunzelle JS; Skiniotis G; Brand M; Shilatifard A; Couture JF
Genes Dev; 2015 Jan; 29(2):123-8. PubMed ID: 25593305
[TBL] [Abstract][Full Text] [Related]
26. Structural Analysis of the Ash2L/Dpy-30 Complex Reveals a Heterogeneity in H3K4 Methylation.
Haddad JF; Yang Y; Takahashi YH; Joshi M; Chaudhary N; Woodfin AR; Benyoucef A; Yeung S; Brunzelle JS; Skiniotis G; Brand M; Shilatifard A; Couture JF
Structure; 2018 Dec; 26(12):1594-1603.e4. PubMed ID: 30270175
[TBL] [Abstract][Full Text] [Related]
27. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases.
Dixit D; Prager BC; Gimple RC; Miller TE; Wu Q; Yomtoubian S; Kidwell RL; Lv D; Zhao L; Qiu Z; Zhang G; Lee D; Park DE; Wechsler-Reya RJ; Wang X; Bao S; Rich JN
Sci Transl Med; 2022 Jan; 14(626):eabf3917. PubMed ID: 34985972
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.
Rocha-Viegas L; Silbermins M; Ogara MF; Pellegrini JM; Nuñez SY; García VE; Vicent GP; Pecci A
Biochim Biophys Acta Gene Regul Mech; 2020 Jan; 1863(1):194475. PubMed ID: 31870784
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Ozyerli-Goknar E; Kala EY; Aksu AC; Bulut I; Cingöz A; Nizamuddin S; Biniossek M; Seker-Polat F; Morova T; Aztekin C; Kung SHY; Syed H; Tuncbag N; Gönen M; Philpott M; Cribbs AP; Acilan C; Lack NA; Onder TT; Timmers HTM; Bagci-Onder T
Cell Commun Signal; 2023 Nov; 21(1):328. PubMed ID: 37974198
[TBL] [Abstract][Full Text] [Related]
30. Guiding COMPASS: Dpy-30 Positions SET1/MLL Epigenetic Signaling.
Dilworth D; Arrowsmith CH
Structure; 2018 Dec; 26(12):1567-1570. PubMed ID: 30517884
[TBL] [Abstract][Full Text] [Related]
31. ASH2L: alternative splicing and downregulation during induced megakaryocytic differentiation of multipotential leukemia cell lines.
Wang J; Zhou Y; Yin B; Du G; Huang X; Li G; Shen Y; Yuan J; Qiang B
J Mol Med (Berl); 2001 Jul; 79(7):399-405. PubMed ID: 11466562
[TBL] [Abstract][Full Text] [Related]
32. Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin.
Bochyńska A; Lüscher-Firzlaff J; Lüscher B
Cells; 2018 Mar; 7(3):. PubMed ID: 29498679
[TBL] [Abstract][Full Text] [Related]
33. Structural implications of Dpy30 oligomerization for MLL/SET1 COMPASS H3K4 trimethylation.
Zhang H; Li M; Gao Y; Jia C; Pan X; Cao P; Zhao X; Zhang J; Chang W
Protein Cell; 2015 Feb; 6(2):147-51. PubMed ID: 25542209
[No Abstract] [Full Text] [Related]
34. lncCPSET1 acts as a scaffold for MLL2/COMPASS to regulate Bmp4 and promote the formation of chicken primordial germ cells.
Ding Y; Zhang C; Zuo Q; Jin K; Li B
Mol Genet Genomics; 2024 Mar; 299(1):41. PubMed ID: 38551742
[TBL] [Abstract][Full Text] [Related]
35. Expression specificity and compensation effect of Ash2l-1/Ash2l-2 in mouse embryonic stem cells.
Xie J; Fan C; Zhang JL; Zhang SQ
Yi Chuan; 2018 Mar; 40(3):237-249. PubMed ID: 29576547
[TBL] [Abstract][Full Text] [Related]
36. The DPY30-H3K4me3 Axis-Mediated PD-L1 Expression in Melanoma.
Zhang Z; Han Y; Sun Q; Wang Y; Sun L
J Inflamm Res; 2022; 15():5595-5609. PubMed ID: 36185638
[TBL] [Abstract][Full Text] [Related]
37. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
38. Disruption of OCT4 Ubiquitination Increases OCT4 Protein Stability and ASH2L-B-Mediated H3K4 Methylation Promoting Pluripotency Acquisition.
Li S; Xiao F; Zhang J; Sun X; Wang H; Zeng Y; Hu J; Tang F; Gu J; Zhao Y; Jin Y; Liao B
Stem Cell Reports; 2018 Oct; 11(4):973-987. PubMed ID: 30269953
[TBL] [Abstract][Full Text] [Related]
39. ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.
Constantin D; Widmann C
Cell Death Dis; 2020 Nov; 11(11):1019. PubMed ID: 33257682
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
